Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company, has scheduled its second quarter 2025 financial results announcement for August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and provide a corporate update.
Additionally, Zymeworks' management will participate in two upcoming investor conferences: the BTIG Virtual Biotechnology Conference on July 29 and the Stifel Biotech Summer Summit from August 11-13, featuring one-on-one meetings and fireside chat presentations.
Zymeworks (NASDAQ: ZYME), un'azienda biotecnologica in fase clinica, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 7 agosto 2025 dopo la chiusura del mercato. La società terrà una conference call e una webcast alle 16:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale.
Inoltre, il management di Zymeworks parteciperà a due prossime conferenze per investitori: la BTIG Virtual Biotechnology Conference il 29 luglio e lo Stifel Biotech Summer Summit dall'11 al 13 agosto, con incontri individuali e presentazioni in formato fireside chat.
Zymeworks (NASDAQ: ZYME), una empresa biotecnológica en fase clínica, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 7 de agosto de 2025 después del cierre del mercado. La compañía realizará una llamada conferencia y una transmisión en vivo a las 4:30 PM ET del mismo día para analizar los resultados y ofrecer una actualización corporativa.
Además, la dirección de Zymeworks participará en dos próximas conferencias para inversores: la BTIG Virtual Biotechnology Conference el 29 de julio y el Stifel Biotech Summer Summit del 11 al 13 de agosto, con reuniones individuales y presentaciones tipo charla junto a la chimenea.
Zymeworks (NASDAQ: ZYME)는 임상 단계의 바이오테크 기업으로, 2025년 2분기 재무 결과 발표를 2025년 8월 7일 장 마감 후에 예정하고 있습니다. 회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜과 웹캐스트를 진행하여 결과를 논의하고 기업 업데이트를 제공할 예정입니다.
또한, Zymeworks 경영진은 7월 29일 BTIG 가상 바이오테크 컨퍼런스와 8월 11일부터 13일까지 열리는 Stifel Biotech Summer Summit에 참석하여 일대일 미팅과 파이어사이드 채팅 발표를 진행할 예정입니다.
Zymeworks (NASDAQ : ZYME), une société de biotechnologie en phase clinique, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 7 août 2025 après la clôture du marché. La société organisera une conférence téléphonique et une webdiffusion à 16h30 ET le même jour pour discuter des résultats et fournir une mise à jour d'entreprise.
De plus, la direction de Zymeworks participera à deux prochaines conférences pour investisseurs : la BTIG Virtual Biotechnology Conference le 29 juillet et le Stifel Biotech Summer Summit du 11 au 13 août, incluant des réunions individuelles et des présentations de type fireside chat.
Zymeworks (NASDAQ: ZYME), ein biotechnologisches Unternehmen in der klinischen Phase, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 7. August 2025 nach Börsenschluss geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Außerdem wird das Management von Zymeworks an zwei bevorstehenden Investorenkonferenzen teilnehmen: der BTIG Virtual Biotechnology Conference am 29. Juli und dem Stifel Biotech Summer Summit vom 11. bis 13. August, mit Einzelgesprächen und Fireside-Chat-Präsentationen.
- None.
- None.
Company to participate in investor conferences in July and August
VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its second quarter 2025 financial results after market close on August 7, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 7, 2025 at 4:30 pm Eastern Time (ET).
The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations.
Management will also participate in the following upcoming investor conferences:
- BTIG Virtual Biotechnology Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on July 29.
- Stifel Biotech Summer Summit: Zymeworks’ management will participate in one-on-one meetings August 11-13 and a fireside chat on August 13 at 9:00 am ET in Newport, Rhode Island.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab has received accelerated approval from the U.S. FDA, conditional approval from China’s NMPA, and conditional marketing authorization from the European Commission for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). It is the first and only dual HER2-targeted bispecific antibody approved for this indication in the U.S., Europe, and China. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug application for ZW251 planned for mid-2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
When will Zymeworks (ZYME) report Q2 2025 earnings?
How can investors access Zymeworks' Q2 2025 earnings call?
Which investor conferences will Zymeworks attend in Summer 2025?
What type of company is Zymeworks (ZYME)?
